The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Minor histocompatibility antigens (MiHAs) are extremely numerous-possibly up to 720 in mice-and have been regarded as an `immunogenetic nightmare' in transplantation. Here, Claude Perreault, Denis Roy and Claudette Fortin summarize evidence showing that most anti-MiHA T-cell responses are oligoclonal, being restricted to several dominant MiHAs, rather than polyclonal. This concept has important implications...
Recent advances in the understanding of the molecular pathogenesis of cancer herald breakthroughs in the treatment of this collection of diseases, which are still usually incurable in advanced stages. In particular, there is a high expectation of gene and immunogene therapy. A recent meetingThe 3rd European Conference on Gene Therapy of Cancer was held at Berlin, Germany, on 11-13 September 1997.
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.